Hydroxychloroquine
Insufficient hydroxychloroquine, excessive prednisone may hinder LLDAS, remission in lupus
DESTIN, Fla. — Low disease activity and remission are achievable for patients with lupus if clinicians “minimize the prednisone” and administer adequate hydroxychloroquine, noted a speaker at the 2023 Congress of Clinical Rheumatology-East.
Despite retinopathy concerns, hydroxychloroquine still proven to boost survival in lupus
DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.
Overall risk for hydroxychloroquine retinopathy low, increases with higher doses
The overall risk for incident retinopathy in patients who received hydroxychloroquine for 5 or more years was low but progressively increased with higher doses, according to researchers.
Macular thickness mapping detects hydroxychloroquine toxicity early, with specificity
KOLOA, Hawaii — Sequential macular thickness mapping can be used to detect retinal toxicity from hydroxychloroquine early and with specificity, according to a speaker here.
Hydroxychloroquine guidelines insufficient to prevent hospitalization for lupus flares
PHILADELPHIA — In patients with systemic lupus erythematosus, lower doses of hydroxychloroquine increase the risk for hospitalization due to flare, according to data presented at ACR Convergence 2022.
Disease control prior to pregnancy nets better outcomes in patients with rheumatic diseases
Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.
No adverse childhood outcomes through 17 years after prenatal hydroxychloroquine exposure
Prenatal exposure to hydroxychloroquine in birthing parents with systemic lupus erythematosus results in no significant adverse outcomes in children from breast feeding through 17 years, according to data published in Rheumatology.
Hydroxychloroquine no longer best treatment for systemic dermatomyositis
DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.
Current hydroxychloroquine use linked to reduced cardiovascular risk in lupus, RA
Current hydroxychloroquine use in patients with rheumatoid arthritis or systemic lupus erythematosus is associated with a reduced risk for cardiovascular events, including ischemic stroke and myocardial infarction, according to data.
Top in rheumatology: Protecting immunocompromised, active psoriatic arthritis treatment
The rheumatology community is looking for ways to protect immunocompromised patients amidst low COVID-19 vaccination rates and poor vaccine response among vulnerable individuals. It was the top story in rheumatology this week.